Grace H. Coughlin

Grace H. Coughlin

Auto-generated profile, based on publicly available information

Grace H. Coughlin

Department of Chemistry and Biochemistry

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2024 in Journal of Behavioral Medicine
Verified
Journal Article
Closed access
PDF file
GCGrace H. Coughlin
Grace H. Coughlin
MAMaximilian Antush
Maximilian Antush
CVChantal A Vella
Chantal A Vella

1 August 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CWCody L. Wolf
Cody L. Wolf
AFAndrea Feci
Andrea Feci
JTJoseph P. Tuccinardi
Joseph P. Tuccinardi
GCGrace H. Coughlin
Grace H. Coughlin
KHKelsey A. Holdaway
Kelsey A. Holdaway
DWDon L. Warner
Don L. Warner
Oncostatin M (OSM) is a proinflammatory cytokine implicated in inflammatory diseases and multiple cancers, especially breast cancer. To date, no federally approved anti-OSM therapeutics exist. We computationally screened ∼1.65 million compounds to identify small-molecule inhibitors (SMIs) of the OSM, and candidates were validated in human breast cancer models. We identified a tetrasubstituted furan (SMI-10) that inhibited OSM signaling, and optimization generated SMI-10B (KD = 12.9 μM) and SMI-10B13 (KD = 6.6 μM). SMI-10B13 strongly inhibited OSM-mediated STAT3 phosphorylation in T47D and MCF-7 cell lines (IC50= 136 and 164 nM, respectively). Fluorescence quenching, NMR, and surface plasmon resonance assays were used to characterize SMI/OSM interactions and identify a number of analogs with low-micromolar affinity for OSM. In a human breast cancer mouse model, SMI-10B13 reduced tumor growth (p < 0.001). Kaplan-Meier analysis showed improved survival in SMI-10B13-treated mice (p = 0.04), highlighting its potential as the first anti-OSM therapeutic to inhibit breast cancer progression and extend survival.